Skip to main content
C.Q. Pharmaceutical Holding Co., Ltd. logo

C.Q. Pharmaceutical Holding Co., Ltd. — Investor Relations & Filings

Ticker · 000950 ISIN · CNE0000010K0 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,883 across all filing types
Latest filing 2024-09-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000950

About C.Q. Pharmaceutical Holding Co., Ltd.

https://www.cqphar.com

C.Q. Pharmaceutical Holding Co., Ltd. is a comprehensive pharmaceutical enterprise specializing in the distribution, retail, and supply chain management of healthcare products. The company operates an extensive network focused on the wholesale of pharmaceuticals and medical devices, providing integrated logistics and warehousing solutions to healthcare providers and manufacturers. Its core business activities encompass the procurement and distribution of a wide range of prescription drugs, over-the-counter medications, and specialized medical equipment. Through its retail pharmacy operations and third-party logistics services, the company facilitates the efficient delivery of medical supplies. C.Q. Pharmaceutical Holding Co., Ltd. emphasizes technological integration within its supply chain to optimize inventory management and ensure the integrity of healthcare products throughout the distribution lifecycle.

Recent filings

Filing Released Lang Actions
关于控股子公司对外发行永续债的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance of perpetual bonds by a controlling subsidiary of the company. It details the issuance plan, authorization matters, and approval procedures. The text does not contain actual financial statements or detailed financial performance data but rather describes a financing activity and the related corporate approvals. The document length is short (1597 characters) and it is clearly an announcement of a capital raising activity. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-09-23 Chinese
关于召开2024年第三次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2024 third extraordinary general meeting of shareholders for Chongqing Pharmaceutical Holdings Co., Ltd. It details the meeting date, voting procedures, registration, and agenda items for shareholder approval. It does not contain financial statements or results but is an announcement related to a shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is 3700 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is PSI.
2024-09-23 Chinese
反舞弊与举报管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '反舞弊与举报管理制度' (Anti-Fraud and Whistleblowing Management System) issued by 重药控股股份有限公司. It outlines the company's governance, internal control, and procedures related to anti-fraud measures, whistleblowing, investigation, reporting, and disciplinary actions. It references company laws, securities laws, internal control standards, and stock exchange listing rules, indicating it is a governance and compliance related document. There are no financial statements, earnings data, or capital structure updates. It is not an announcement or a brief summary but a comprehensive internal governance policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-09-23 Chinese
北京市竞天公诚律师事务所关于重药控股股份有限公司2024年第二次临时股东会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and voting results of a company's 2024 second extraordinary shareholders' meeting. It details the legality and compliance of the meeting process, attendees' qualifications, and voting outcomes. It does not contain financial statements, management discussion, or detailed financial results. It is not an announcement of a report but a legal certification related to a shareholders' meeting. The content aligns with a Declaration of Voting Results & Voting Rights Announcements (DVA) filing, as it reports official voting results and meeting procedural legality.
2024-09-05 Chinese
2024年第二次临时股东会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary shareholders meeting of Chongqing Pharmaceutical Holdings Co., Ltd. It details the meeting date, voting procedures, attendance, and the voting results on a proposal to change directors. It also includes a legal opinion confirming the validity of the meeting and voting process. The document is an official disclosure of voting results from a shareholders meeting, not a report or presentation. It fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and contains detailed voting results, confirming it is not merely a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2024-09-05 Chinese
关于召开2024年第二次临时股东会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the 2024 second extraordinary general meeting of shareholders (临时股东会) for Chongqing Pharmaceutical Holdings Co., Ltd. It includes information on the meeting date, voting procedures (both onsite and online), eligibility, registration details, and agenda items such as the election of a director. The document does not contain financial statements or results but is a notice informing shareholders about the meeting and how to participate and vote. It is not a report itself but an announcement related to a shareholder meeting. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories like AGM Information or Declaration of Voting Results (which would come after the meeting). The document length is under 5,000 characters, consistent with an announcement rather than a full report.
2024-09-02 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.